ClinicalTrials.govpublic full text
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
non-small cell lung cancer
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 394764
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.